Clinical Trials · NCT06300216
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
- Phase
- N/A
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Enrollment
- 500
- Start date
- Mar 2024
- Locations
- 1 site, China
- Primary endpoint
- Treatment Emergent Adverse Events